Orgenesis(US:ORGS) globenewswire.com·2024-05-21 11:00Core Insights - Orgenesis Inc. is advancing the commercialization of its decentralized platform through its subsidiary Octomera, which includes the deployment of Orgenesis Mobile Processing Units and Labs (OMPULs) to improve access to cell and gene therapies (CGT) [2][3] - The company regained full ownership of Octomera, enhancing its control over the subsidiary and supporting the development of its proprietary therapeutic pipeline, particularly in immune-oncology [2] - A strategic partnership with Germfree aims to co-market Orgenesis' decentralized services, leveraging Germfree's global network to accelerate market entry and focus on therapeutic development [3] Financial Performance - For Q1 2024, Orgenesis reported revenue of $141,000, a slight decrease from $142,000 in Q1 2023 [11] - The cost of revenues significantly decreased to $492,000 from $2.72 million in the same period last year, resulting in a gross loss of $351,000 compared to a gross loss of $2.58 million in Q1 2023 [11] - The operating loss for Q1 2024 was $8.93 million, down from $19.6 million in Q1 2023, indicating improved operational efficiency [11] Funding and Investments - The company secured approximately $2.5 million in investments from accredited investors, including healthcare professionals, during March and April 2024 [3] - Orgenesis has been awarded over $50 million in potential future grant funding to support its development activities, which will aid in advancing its therapeutic pipeline [3] Ownership and Shareholder Actions - On May 21, 2024, shareholders agreed to exchange approximately $16 million of debt for 15.8 million shares of common stock, demonstrating strong support for the company's strategic direction [3]